108 related articles for article (PubMed ID: 32718536)
1. Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib.
Zheng Q; Fang W; Huang Y; Gan J; Zhang L
J Thorac Oncol; 2020 Aug; 15(8):e132-e133. PubMed ID: 32718536
[No Abstract] [Full Text] [Related]
2. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
Song M; Kim SH; Yoon SK
Arch Pharm Res; 2015 Dec; 38(12):2120-3. PubMed ID: 26377589
[TBL] [Abstract][Full Text] [Related]
3. RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report.
Wang Y; Xu Y; Wang X; Sun C; Guo Y; Shao G; Yang Z; Qiu S; Ma K
Medicine (Baltimore); 2019 Jan; 98(3):e14120. PubMed ID: 30653139
[TBL] [Abstract][Full Text] [Related]
4. RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.
Sarfaty M; Moore A; Neiman V; Dudnik E; Ilouze M; Gottfried M; Katznelson R; Nechushtan H; Sorotsky HG; Paz K; Katz A; Saute M; Wolner M; Moskovitz M; Miller V; Elvin J; Lipson D; Ali S; Gutman LS; Dvir A; Gordon N; Peled N
Clin Lung Cancer; 2017 Jul; 18(4):e223-e232. PubMed ID: 28082048
[TBL] [Abstract][Full Text] [Related]
5. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
Drilon A; Wang L; Hasanovic A; Suehara Y; Lipson D; Stephens P; Ross J; Miller V; Ginsberg M; Zakowski MF; Kris MG; Ladanyi M; Rizvi N
Cancer Discov; 2013 Jun; 3(6):630-5. PubMed ID: 23533264
[TBL] [Abstract][Full Text] [Related]
6. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.
Mukhopadhyay S; Pennell NA; Ali SM; Ross JS; Ma PC; Velcheti V
J Thorac Oncol; 2014 Nov; 9(11):1714-9. PubMed ID: 25436805
[TBL] [Abstract][Full Text] [Related]
7. The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
Zhu YC; Wang WX; Zhang QX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
Clin Lung Cancer; 2019 Jan; 20(1):e73-e76. PubMed ID: 30366769
[No Abstract] [Full Text] [Related]
8. The new kid on the block: RET in lung cancer.
Gainor JF; Shaw AT
Cancer Discov; 2013 Jun; 3(6):604-6. PubMed ID: 23749525
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T
Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Huang Q; Schneeberger VE; Luetteke N; Jin C; Afzal R; Budzevich MM; Makanji RJ; Martinez GV; Shen T; Zhao L; Fung KM; Haura EB; Coppola D; Wu J
Mol Cancer Ther; 2016 Oct; 15(10):2521-2529. PubMed ID: 27496134
[TBL] [Abstract][Full Text] [Related]
11. A novel TNIP2-RET fusion identified in a patient with mucinous adenocarcinoma of the lung.
Ren P; Luo N; Qi Y; Wu Y; Jin M
Lung Cancer; 2021 Mar; 153():179-181. PubMed ID: 33478856
[No Abstract] [Full Text] [Related]
12. Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma.
Go H; Jung YJ; Kang HW; Park IK; Kang CH; Lee JW; Ju YS; Seo JS; Chung DH; Kim YT
Lung Cancer; 2013 Oct; 82(1):44-50. PubMed ID: 23932363
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics and Molecular Patterns of
Zhang K; Chen H; Wang Y; Yang L; Zhou C; Yin W; Wang G; Mao X; Xiang J; Li B; Zhang T; Fei S
Oncol Res; 2019 May; 27(5):575-582. PubMed ID: 30131091
[No Abstract] [Full Text] [Related]
14. Small Cell Transformation in a Patient With
Dimou A; Lo YC; Merrell KW; Halling KC; Mansfield AS
JCO Precis Oncol; 2022 Dec; 6():e2200478. PubMed ID: 36542817
[No Abstract] [Full Text] [Related]
15. A Novel Intergenic LSM14A-RET Fusion Variant in a Patient With Lung Adenocarcinoma.
Lv Y; Ling F; Zhang J; Xiao M; Mao W
J Thorac Oncol; 2020 Apr; 15(4):e52-e53. PubMed ID: 32216946
[No Abstract] [Full Text] [Related]
16. [Detection of novel driver mutations in liquid biopsy: case report of a RET-positive lung adenocarcinoma treated with pralsetinib.].
Russano M
Recenti Prog Med; 2021 Jan; 112(1):5e-9e. PubMed ID: 33512366
[TBL] [Abstract][Full Text] [Related]
17. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway.
Lin C; Wang S; Xie W; Zheng R; Gan Y; Chang J
Oncotarget; 2016 Sep; 7(37):59236-59244. PubMed ID: 27494860
[TBL] [Abstract][Full Text] [Related]
18. RET-Rearranged Lung Adenocarcinoma with Paraneoplastic Meige Syndrome.
Abbar B; Henry C; Theou-Anton N; Brosseau S; Nguenang M; Pluvy J; Assoun S; Zalcman G; Gounant V
J Thorac Oncol; 2019 Nov; 14(11):e250-e251. PubMed ID: 31668323
[No Abstract] [Full Text] [Related]
19. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
[TBL] [Abstract][Full Text] [Related]
20. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
